Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$214.2m

Voyager Therapeutics Future Growth

Future criteria checks 0/6

Voyager Therapeutics's earnings are forecast to decline at 13.4% per annum while its annual revenue is expected to grow at 0.2% per year. EPS is expected to grow by 0.8% per annum. Return on equity is forecast to be -42.4% in 3 years.

Key information

-13.4%

Earnings growth rate

0.8%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate0.2%
Future return on equity-42.4%
Analyst coverage

Good

Last updated13 Mar 2025

Recent future growth updates

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recent updates

Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump

Feb 25
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump

Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance

Jan 30

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Voyager Therapeutics hires new finance chief

Sep 07

Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02

Aug 04

Earnings and Revenue Growth Forecasts

NasdaqGS:VYGR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202773-132-101-739
12/31/202666-117-114-9612
12/31/202566-105-96-9112
12/31/202480-65-19-15N/A
9/30/202416426-29-25N/A
6/30/20241449-22-18N/A
3/31/2024119-3813N/A
12/31/20232501327578N/A
9/30/2023158528689N/A
6/30/2023195969194N/A
3/31/2023191997477N/A
12/31/202241-46-15-13N/A
9/30/202271-17911N/A
6/30/202231-6046N/A
3/31/202232-7112N/A
12/31/202137-71-55-54N/A
9/30/202116-93-92-87N/A
6/30/202113218-100-91N/A
3/31/202116039-100-89N/A
12/31/202017137-109-97N/A
9/30/202019740-110-98N/A
6/30/2020100-61-103-95N/A
3/31/2020117-41-113-105N/A
12/31/2019104-444149N/A
9/30/201974-544348N/A
6/30/201955-594752N/A
3/31/201912-965761N/A
12/31/20188-88-20-16N/A
9/30/201812-78N/A-6N/A
6/30/201811-81N/A-5N/A
3/31/201810-74N/A2N/A
12/31/201710-71N/A-61N/A
9/30/20176-74N/A-60N/A
6/30/20178-59N/A-54N/A
3/31/201711-50N/A-47N/A
12/31/201614-40N/A-42N/A
9/30/201617-34N/A-39N/A
6/30/201618-32N/A-36N/A
3/31/201620-30N/A-33N/A
12/31/201517-38N/A41N/A
9/30/201512-35N/A46N/A
6/30/20157-32N/A50N/A
3/31/20153-30N/A55N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VYGR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VYGR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VYGR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VYGR's revenue (0.2% per year) is forecast to grow slower than the US market (8.4% per year).

High Growth Revenue: VYGR's revenue (0.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VYGR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 02:40
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Voyager Therapeutics, Inc. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jack AllenBaird
Aydin HuseynovBenchmark Company